Achievement of Pathological Complete Response with Neoadjuvant Ensartinib in a Patient with Locally Advanced ALK-Rearranged Lung Squamous Cell Carcinoma: A Case Report and Literature Review
This case report demonstrates that neoadjuvant treatment with ensartinib combined with chemotherapy achieved a pathological complete response in a patient with locally advanced ALK-rearranged lung squamous cell carcinoma, a rare subtype lacking established neoadjuvant guidelines.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The Tiny Switch and the Big Puzzle
Imagine your body is a bustling city where cells are the citizens, constantly following a set of instructions to grow, work, and eventually retire. Sometimes, a tiny glitch happens in the instruction manual—a "typo" in the DNA code—that tells a cell to ignore the "stop" sign and keep growing out of control. This is how cancer starts. In the lungs, there's a specific kind of glitch involving a protein called ALK (Anaplastic Lymphoma Kinase). Think of ALK as a light switch that gets stuck in the "ON" position, flooding the cell with energy and causing it to multiply wildly.
Most of the time, this "stuck switch" happens in a specific type of lung cancer called adenocarcinoma, which is like the most common neighborhood in the city. However, it's extremely rare to find this same broken switch in a different neighborhood called squamous cell carcinoma. For a long time, doctors didn't have a clear plan for how to fix this rare problem, especially when the cancer had already spread to nearby lymph nodes (making it "locally advanced"). The big question was: Could we use a special "key" (a targeted drug) to turn that stuck switch off before surgery, shrinking the tumor so a surgeon could remove it completely? This story is about a brave attempt to answer that question.
The Case of the Vanishing Tumor
This paper tells the story of a 40-year-old woman who never smoked but developed a cough that wouldn't go away. When doctors looked inside her chest, they found a small tumor in her left lung and several enlarged lymph nodes nearby. A biopsy revealed she had squamous cell lung cancer, a type usually not associated with the ALK glitch. However, a genetic test confirmed the surprise: she did have the EML4-ALK fusion mutation. It was like finding a rare, specific key in a lock that usually doesn't even have a keyhole.
The doctors decided to try a new strategy. Instead of just cutting the tumor out immediately, they gave her a "pre-game" treatment called neoadjuvant therapy. Think of this as sending a specialized cleanup crew to shrink the mess before the main demolition team arrives. The crew consisted of three members:
- Ensartinib: A targeted drug designed specifically to jam that stuck ALK switch.
- Nab-paclitaxel and Cisplatin: Two chemotherapy drugs that act like a general cleanup crew, attacking fast-growing cells.
The patient took this combination for three cycles (about three months). During this time, she developed a rash (a common side effect, like a sunburn), but it was manageable with cream. When they scanned her chest again, the results were exciting: the main tumor and the swollen lymph nodes had shrunk significantly.
Then came the surgery. The doctors performed a video-assisted thoracoscopic surgery (VATS), which is a minimally invasive operation using small cameras and tools. When they examined the removed tissue under a microscope, something incredible happened. They couldn't find a single living cancer cell. The tissue looked like a battlefield after the war: there was scar tissue, inflammation, and some debris, but no enemy soldiers remained. This is called a Pathological Complete Response (pCR). It means the treatment wiped out the cancer so thoroughly that the surgery was essentially removing an empty shell.
The patient recovered well, continued taking the targeted drug to keep the cancer away, and at her last check-up in February 2026, there was no sign of the disease returning.
What This Means (And What It Doesn't)
This case is a big "what if" turned into a "wow." It suggests that using a targeted drug like ensartinib combined with chemotherapy before surgery might be a powerful way to treat locally advanced lung cancer, even in the rare squamous cell type. The authors point out that while we have seen good results with this approach in the more common adenocarcinoma type, this is one of the first times it has worked so perfectly in squamous cell cancer.
However, the paper is careful not to shout "We solved it!" just yet. The authors emphasize that this is just one patient. They note that there are currently no official rules or guidelines telling doctors to do this for everyone. Other studies mentioned in the paper show that different drugs (like alectinib or brigatinib) can also shrink tumors and help surgeons, but the results vary. Some studies show great success, while others are still waiting for long-term data to see if patients stay cancer-free for years.
The paper concludes that while this specific story is a promising sign, we need more research. We need larger studies to see if this works for other people and to make sure it's safe in the long run. For now, this case is a bright spark of hope, showing that even rare cancers might be vulnerable to the right combination of keys and cleaners, but the full picture is still being painted.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.